6667 Stock Overview
A genetic testing platform company, provides consumer genetic testing and cancer screening services in China.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Mega Genomics Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$9.17 |
52 Week High | HK$12.40 |
52 Week Low | HK$7.68 |
Beta | 1.56 |
11 Month Change | -2.96% |
3 Month Change | -4.38% |
1 Year Change | -6.05% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -49.06% |
Recent News & Updates
Recent updates
Some Investors May Be Worried About Mega Genomics' (HKG:6667) Returns On Capital
May 03Calculating The Intrinsic Value Of Mega Genomics Limited (HKG:6667)
Feb 20Mega Genomics Limited's (HKG:6667) Share Price Could Signal Some Risk
Aug 12A Look At The Fair Value Of Mega Genomics Limited (HKG:6667)
Nov 07Shareholder Returns
6667 | HK Healthcare | HK Market | |
---|---|---|---|
7D | -3.4% | -1.4% | -0.1% |
1Y | -6.0% | -29.4% | -3.2% |
Return vs Industry: 6667 exceeded the Hong Kong Healthcare industry which returned -29.4% over the past year.
Return vs Market: 6667 underperformed the Hong Kong Market which returned -3.2% over the past year.
Price Volatility
6667 volatility | |
---|---|
6667 Average Weekly Movement | 4.9% |
Healthcare Industry Average Movement | 5.8% |
Market Average Movement | 6.5% |
10% most volatile stocks in HK Market | 13.5% |
10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 6667 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6667's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2016 | 229 | n/a | www.megagenomics.cn |
Mega Genomics Limited, a genetic testing platform company, provides consumer genetic testing and cancer screening services in China. It offers general testing services, including brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; and cardiovascular and cerebrovascular disease risk assessment packages. The company also provides advanced testing services, such as hereditary breast cancer/ovarian cancer genetic testing; Septin9 colorectal cancer screening test; RNF180/Septin9 gastric cancer screening test; and telomere length genetic testing that assesses the cell age and aging rate of a person.
Mega Genomics Limited Fundamentals Summary
6667 fundamental statistics | |
---|---|
Market cap | HK$2.14b |
Earnings (TTM) | HK$32.62m |
Revenue (TTM) | HK$164.28m |
65.8x
P/E Ratio13.1x
P/S RatioIs 6667 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6667 income statement (TTM) | |
---|---|
Revenue | CN¥151.30m |
Cost of Revenue | CN¥63.00m |
Gross Profit | CN¥88.30m |
Other Expenses | CN¥58.26m |
Earnings | CN¥30.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.13 |
Gross Margin | 58.36% |
Net Profit Margin | 19.85% |
Debt/Equity Ratio | 3.5% |
How did 6667 perform over the long term?
See historical performance and comparison